{"title":"Development of an Efficient Alternative Synthesis of the Endothelin Receptor Antagonist Bosentan","authors":"Jigar Panchal , Namita Misra , Meenu Devi , Ashima Sharma , Sonika Jain , Pankaj Jain , Jaya Dwivedi , Swapnil Sharma","doi":"10.1080/00304948.2023.2170665","DOIUrl":null,"url":null,"abstract":"Pulmonary artery hypertension (PAH), is characterized by pulmonary vascular resistance that may lead to heart failure. 1 – 2 Endothelin receptor antagonists (ERAs) have been considered as rational targets in the therapy of PAH. 3 Bosentan monohydrate (brand name Tracleer V R ) is the first orally administered drug approved by the U.S. Food and Drug Administration indicated for the therapy of PAH. 4 Bosentan (4-( tert -butyl)- N -(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2 ’ -bipyrimidin]-4-yl)benzenesulfonamide (","PeriodicalId":19681,"journal":{"name":"Organic Preparations and Procedures International","volume":"55 5","pages":"Pages 404-410"},"PeriodicalIF":1.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Organic Preparations and Procedures International","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/org/science/article/pii/S0030494823000205","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, ORGANIC","Score":null,"Total":0}
引用次数: 0
Abstract
Pulmonary artery hypertension (PAH), is characterized by pulmonary vascular resistance that may lead to heart failure. 1 – 2 Endothelin receptor antagonists (ERAs) have been considered as rational targets in the therapy of PAH. 3 Bosentan monohydrate (brand name Tracleer V R ) is the first orally administered drug approved by the U.S. Food and Drug Administration indicated for the therapy of PAH. 4 Bosentan (4-( tert -butyl)- N -(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2 ’ -bipyrimidin]-4-yl)benzenesulfonamide (
肺动脉高压（PAH）的特点是肺血管阻力可能导致心力衰竭。1–2内皮素受体拮抗剂（ERAs）被认为是治疗PAH的合理靶点。3波生坦一水合物（商标名Tracleer V R）是美国食品药品监督管理局批准的第一种用于治疗PAH的口服药物。4-波生坦（4-（叔丁基）-N-（6-（2-羟基乙氧基）-5-（2-甲氧基苯氧基）-[2,2'-双嘧啶]-4-基）苯磺酰胺(
期刊介绍：
Organic Preparations and Procedures International (OPPI) publishes important, bimonthly research relevant to organic chemists engaged in synthesis. It is devoted to preparative organic chemistry, organometallic compounds, and procedures generally related to synthesis. The mission has always been to assist the practitioner by publishing reliable and reproducible procedures of the highest standards.
OPPI publishes articles in every area of preparative organic chemistry - from innovative technology to improvements in traditional synthesis. Along with experimental papers, the Journal publishes authoritative reviews on significant topics in synthesis.
The editors work closely with all authors, including those whose first language may not be English, to ensure important work is provided with clarity and a forum, giving OPPI a truly unique opportunity to serve a worldwide audience with valuable material.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
